Iovance Biotherapeutics to Present at Key Investor Conferences — Iovance Biotherapeutics, Inc.

Event summary

Iovance Biotherapeutics will present at Wells Fargo's 21st Annual Healthcare Conference on September 10, 2026.
The company will also present at H.C. Wainwright's 28th Annual Global Investment Conference on September 15, 2026.
Iovance is the global leader in TIL cell therapies, with Amtagvi® approved in three markets and available at over 95 treatment centers.
The company's TIL platform includes next-generation programs in solid tumors, gene-edited and IL-12 tethered TIL therapies, and precision immuno-oncology approaches.

The big picture

Iovance Biotherapeutics is positioning itself as a leader in the TIL cell therapy space, with a focus on expanding its commercial footprint and advancing its pipeline. The upcoming investor conferences provide a platform for the company to communicate its strategic vision and growth prospects in a competitive oncology market. The approval of Amtagvi® in multiple markets and its availability at numerous treatment centers underscore the company's progress in making TIL therapies accessible to a broader patient population.

What we're watching

Commercial Expansion: The pace at which Iovance can expand the availability of Amtagvi® beyond the current 95 treatment centers.
Pipeline Progress: Whether Iovance's next-generation TIL therapies will advance through clinical trials and contribute to revenue growth.
Market Positioning: How Iovance's strategic messaging at these conferences will influence investor perception and stock performance.